Skip to content
GLP-1 Scorecard
Menu
Graded #340

Bliv

Bliv is a telehealth provider selling personalized compounded GLP-1 programs.

Visit BlivWe may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Semaglutide
$116/mo (as low as, varies by plan and eligibility, compounded)
Tirzepatide
$199/mo (as low as, varies by plan and eligibility, compounded)
Coverage
Coverage not published
Brand-name
Compounded only

Weigh Bliv against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives. Because Bliv dispenses compounded medication, it’s worth understanding whether compounded semaglutide is legit and safe.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value71/100
Dose & formulation64/100
Clinical oversight55/100
Labs & monitoring53/100
Fulfillment65/100
Contract terms45/100

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • The advertised rates are 'as low as' figures footnoted 'based on plan structure and eligibility', and the plan selector sits behind the medical intake — the rate you are offered is not knowable before you hand over a medical history
  • A $24.99 provider consultation fee is charged on top, and the refund policy deducts $200 for 'clinical coordination and account setup'
  • The homepage advertises 'no long-term commitments or cancellation fees' while the terms require the membership fee to be paid 'in a single sum', call it non-refundable and refer to a 'Membership Term'
  • The only figure smaller than the advertised rate is a $29 CareCredit/Klarna installment, which is a financing payment rather than the price of a month of medication
  • FDA issued Bliv Wellness LLC dba Bliv a warning letter in February 2026; the letter is public in FDA's warning-letter database

Bottom line — Grade C

Best for: Shoppers who want mainstream telehealth GLP-1 access.

Ranked #340 of 544 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.

FDAWarning letter issued to Bliv Wellness LLC dba Bliv in February 2026. See the FDA warning-letter database.

Closest here

The rankings grading nearest Bliv — the realistic shortlist.

The 18 rankings nearest this one

View full scorecard rankings →

Pricing/verification reflect Bliv's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Bliv's site. Not medical advice; see our disclosure.

← Back to the scorecard